Surgical Oncology Principles — MCQs

Surgical Oncology Principles Indian Medical PG Practice Questions and MCQs

Question 31: A female patient presented with severe secretory diarrhea was diagnosed with medullary thyroid carcinoma (MTC). What is the primary treatment for MTC?

A. Surgery and Radiotherapy
B. Radiotherapy and Chemotherapy
C. Surgery only (Correct Answer)
D. Radioiodine ablation

Explanation: **Explanation:** **Medullary Thyroid Carcinoma (MTC)** arises from the **parafollicular C-cells**, which are neuroendocrine cells derived from the neural crest. These cells secrete **calcitonin**, which often serves as a tumor marker. In some cases, high levels of calcitonin or other peptides (like VIP) can cause systemic symptoms such as secretory diarrhea. 1. **Why "Surgery only" is correct:** The primary and most effective treatment for MTC is **Total Thyroidectomy with Central Neck Dissection (Level VI)**. Since MTC does not concentrate iodine and is generally resistant to conventional chemotherapy and radiation, surgical clearance is the only curative modality. If lymph nodes are clinically positive, a lateral neck dissection is also performed. 2. **Why other options are incorrect:** * **Radioiodine (I-131) ablation:** This is used for differentiated thyroid cancers (Papillary/Follicular) arising from follicular cells. Since C-cells do not take up iodine, I-131 has **no role** in MTC. * **Radiotherapy:** It is not a primary treatment and is reserved only for palliative care or local recurrence that cannot be surgically resected. * **Chemotherapy:** MTC is notoriously chemo-resistant. Targeted therapies (Tyrosine Kinase Inhibitors like **Vandetanib** or **Cabozantinib**) are used only for metastatic or progressive disease, not as primary treatment. **High-Yield Clinical Pearls for NEET-PG:** * **Screening:** All patients with MTC must be screened for **MEN 2A/2B** syndromes (specifically checking for Pheochromocytoma via urinary metanephrines before surgery). * **Genetic Testing:** *RET* proto-oncogene mutation testing is mandatory for the patient and first-degree relatives. * **Tumor Markers:** Calcitonin (for diagnosis/recurrence) and CEA (for prognosis). * **Prophylactic Surgery:** In *RET* mutation carriers, prophylactic thyroidectomy is recommended (age depends on the specific codon mutation).

Question 32: What is the most common tumor of the anterior mediastinum?

A. Thymoma (Correct Answer)
B. Lymphoma
C. Germ cell tumor
D. Thyroid tumors

Explanation: **Explanation:** The anterior mediastinum is the most common site for mediastinal masses. The differential diagnosis is classically remembered by the **"4 Ts"**: **T**hymoma, **T**errible Lymphoma, **T**eratoma (Germ cell tumors), and **T**horacic thyroid. **Why Thymoma is Correct:** Among these, **Thymoma** is the most common primary tumor of the anterior mediastinum in adults (accounting for approximately 30-50% of cases). It typically presents in the 4th to 6th decades of life and is famously associated with paraneoplastic syndromes, most notably **Myasthenia Gravis** (seen in 30-45% of thymoma patients). **Analysis of Incorrect Options:** * **Lymphoma:** While common in the anterior mediastinum (especially in children and young adults), it is less frequent than thymoma in the general adult population. It often presents with systemic "B symptoms" and bulky lymphadenopathy. * **Germ Cell Tumors (GCTs):** These include benign teratomas (most common GCT) and malignant types like seminomas. While significant, they are less common than thymomas. * **Thyroid Tumors:** Retrosternal goiters or thyroid neoplasms can descend into the anterior mediastinum, but they are considered "intruders" rather than the most common primary mediastinal tumor. **High-Yield Clinical Pearls for NEET-PG:** * **Most common mediastinal mass overall:** Neurogenic tumors (but these are located in the **posterior** mediastinum). * **Myasthenia Gravis Association:** While 30-45% of Thymoma patients have Myasthenia Gravis, only about 10-15% of Myasthenia Gravis patients actually have a Thymoma. * **Imaging Gold Standard:** Contrast-Enhanced CT (CECT) is the investigation of choice for evaluating mediastinal masses. * **Surgical Approach:** Median sternotomy is the traditional approach for thymectomy.

Question 33: Sentinel lymph node biopsy is an important part of the management of which of the following conditions?

A. Carcinoma prostate
B. Carcinoma breast (Correct Answer)
C. Carcinoma lung
D. Carcinoma nasopharynx

Explanation: **Explanation:** **1. Why Carcinoma Breast is Correct:** The **Sentinel Lymph Node (SLN)** is defined as the first lymph node(s) in a regional lymphatic basin that receives drainage from a primary tumor. In breast cancer management, SLN biopsy (SLNB) is the standard of care for clinically node-negative (cN0) patients. It allows for accurate pathological staging while avoiding the morbidity of an Axillary Lymph Node Dissection (ALND), such as lymphedema, nerve injury, and shoulder dysfunction. If the SLN is negative for metastasis, the remaining axillary nodes are highly likely to be negative, sparing the patient further surgery. **2. Why the Other Options are Incorrect:** * **Carcinoma Prostate:** Staging typically involves a pelvic lymph node dissection (PLND) during radical prostatectomy or imaging/nomograms. SLNB is not standard practice. * **Carcinoma Lung:** Staging relies on CT/PET imaging and invasive techniques like EBUS-TBNA (Endobronchial Ultrasound) or mediastinoscopy. The complex, non-linear lymphatic drainage of the lung makes SLNB unreliable. * **Carcinoma Nasopharynx:** This is primarily treated with radiotherapy and chemotherapy. Surgical nodal assessment via SLNB is not part of the management protocol as the neck is usually treated with elective or therapeutic radiation. **3. High-Yield Clinical Pearls for NEET-PG:** * **Technique:** SLNB is most commonly performed using a "dual technique" (Technetium-99m labeled sulfur colloid and Isosulfan/Methylene blue dye). * **Indications:** Besides Breast Cancer, SLNB is the standard of care for **Malignant Melanoma** (Breslow thickness >0.75 mm or <0.75 mm with ulceration). * **Contraindications in Breast Cancer:** Inflammatory breast cancer, clinically palpable nodes (cN1), and large tumors (T3/T4) generally preclude SLNB. * **Identification:** The node is identified by the "10% rule" (any node with ≥10% of the radioactivity of the hottest node) or if it is visibly blue.

Question 34: A patient presents with a stony hard, painless lymph node in the left supraclavicular fossa. A biopsy report states squamous cell carcinoma. What is the most likely diagnosis?

A. Stomach carcinoma
B. Breast carcinoma
C. Lung carcinoma (Correct Answer)
D. Pancreas carcinoma

Explanation: ### Explanation **1. Why Lung Carcinoma is Correct:** The presence of a stony hard, painless lymph node in the left supraclavicular fossa is known as **Virchow’s node (Troisier’s sign)**. While Virchow’s node is classically associated with abdominal malignancies (via the thoracic duct), the **histopathology** is the deciding factor here. * **Squamous cell carcinoma (SCC)** in a supraclavicular node most commonly originates from the **lung** (especially the upper lobes), esophagus, or head and neck region. * Primary lung cancers (especially SCC and small cell) frequently metastasize to the supraclavicular chain. **2. Why Other Options are Incorrect:** * **Stomach Carcinoma:** This is the most common cause of Virchow’s node overall. However, gastric cancer is an **adenocarcinoma**. If the biopsy had shown glandular patterns or mucin-producing cells, this would be the top choice. * **Breast Carcinoma:** Breast cancer typically metastasizes to the axillary nodes first. When it involves the supraclavicular nodes, the histology is almost always **adenocarcinoma** (ductal or lobular). * **Pancreas Carcinoma:** Similar to gastric cancer, pancreatic malignancies are **adenocarcinomas**. They can present with a Virchow’s node, but not with squamous histology. **3. NEET-PG High-Yield Pearls:** * **Virchow’s Node:** Located in the left supraclavicular fossa, between the heads of the sternocleidomastoid muscle. * **Troisier’s Sign:** The clinical finding of a palpable Virchow’s node, signifying occult visceral malignancy. * **Right Supraclavicular Node:** More commonly associated with malignancies of the **mediastinum, right lung, or esophagus**. * **Sister Mary Joseph’s Nodule:** Periumbilical lymphadenopathy associated with intra-abdominal malignancy (most commonly gastric). * **Irish’s Node:** Left axillary lymph node involvement in gastric cancer.

Question 35: Thyroxine can be given in which type of thyroid carcinoma?

A. Papillary (Correct Answer)
B. Medullary
C. Anaplastic
D. Undifferentiated

Explanation: **Explanation:** The correct answer is **Papillary Thyroid Carcinoma (PTC)**. **Why Papillary is Correct:** Papillary and Follicular carcinomas are classified as **Differentiated Thyroid Cancers (DTC)**. These tumors arise from follicular cells and often retain the physiological characteristics of normal thyroid tissue, including the expression of **TSH receptors**. TSH (Thyroid Stimulating Hormone) acts as a growth factor for these malignant cells. By administering exogenous **Thyroxine (T4)** in supraphysiological doses, we achieve **TSH suppression** via the negative feedback loop. This reduces the stimulus for tumor growth, decreases recurrence rates, and improves survival in DTC patients. **Why Other Options are Incorrect:** * **Medullary Thyroid Carcinoma (B):** This tumor arises from **Parafollicular C-cells**, which secrete calcitonin. C-cells do not possess TSH receptors; therefore, TSH suppression with Thyroxine has no therapeutic effect on tumor growth. * **Anaplastic (C) and Undifferentiated (D) Carcinoma:** These are highly aggressive, pleomorphic tumors that have lost all functional characteristics of thyroid follicular cells, including TSH receptors. They do not respond to hormonal manipulation. **NEET-PG High-Yield Pearls:** * **Target TSH Levels:** In high-risk DTC, the goal is typically TSH <0.1 mU/L. In low-risk patients, it is 0.1–0.5 mU/L. * **Monitoring:** Serum **Thyroglobulin (Tg)** is used as a tumor marker for follow-up in PTC after total thyroidectomy. * **Radioactive Iodine (RAI):** PTC also takes up RAI (I-131) because it retains the sodium-iodide symporter (NIS), unlike Medullary or Anaplastic types. * **Most Common:** Papillary is the most common thyroid cancer and has the best prognosis.

Question 36: Lymphatic spread is the most common route in which of the following thyroid carcinomas?

A. Papillary (Correct Answer)
B. Follicular
C. Medullary
D. Anaplastic

Explanation: **Explanation:** The route of metastasis in thyroid malignancies is a high-yield topic for NEET-PG. The correct answer is **Papillary Thyroid Carcinoma (PTC)** because its hallmark biological behavior is early and frequent spread via the **lymphatic system**. * **Papillary Carcinoma (Option A):** This is the most common thyroid cancer. It is characterized by an indolent course but has a high propensity for lymphatic spread to the cervical (level II-V) and central (level VI) lymph nodes. Up to 50-80% of patients may have microscopic nodal involvement at the time of diagnosis. * **Follicular Carcinoma (Option B):** Unlike PTC, Follicular Thyroid Carcinoma (FTC) typically spreads via the **hematogenous (bloodborne) route**. This is because FTC tends to invade small blood vessels (angioinvasion), leading to distant metastases in the lungs and bones. Lymph node involvement is rare (<10%). * **Medullary Carcinoma (Option C):** While MTC spreads to both lymph nodes and blood, it is less common than PTC. It arises from parafollicular C-cells and is often associated with MEN 2 syndromes. * **Anaplastic Carcinoma (Option D):** This is a highly aggressive tumor that spreads rapidly via direct local invasion into surrounding neck structures, as well as through both lymphatic and hematogenous routes. **High-Yield Clinical Pearls:** * **PTC:** Most common thyroid cancer; associated with radiation exposure; features **Psammoma bodies** and **Orphan Annie eye nuclei**. * **FTC:** Associated with iodine deficiency; cannot be diagnosed by FNAC (requires histology to see capsular/vascular invasion). * **MTC:** Marker is **Calcitonin**; screening for *RET* proto-oncogene is essential. * **Rule of Thumb:** "Papillary = Popular (most common) & Peripheral (lymph nodes); Follicular = Far (distant blood spread)."

Question 37: What is meant by Stage IIIc of colon cancer?

A. Hepatic metastasis
B. Extension up to the serosa and lymph node involvement (Correct Answer)
C. Extension up to the serosa
D. Extension up to the mucosa

Explanation: ### Explanation The staging of colon cancer follows the **AJCC TNM Classification**. Understanding the progression from Stage I to IV is crucial for NEET-PG, as it dictates both prognosis and the need for adjuvant chemotherapy. **1. Why Option B is Correct:** Stage III colon cancer is defined by the presence of **lymph node involvement (N1 or N2)**, regardless of the depth of the primary tumor (T), provided there are no distant metastases (M0). Specifically, **Stage IIIc** represents advanced local disease with significant nodal involvement. In the TNM system, "extension up to the serosa" corresponds to **T3 or T4** lesions. When combined with positive lymph nodes, the cancer is classified under the Stage III umbrella. **2. Analysis of Incorrect Options:** * **Option A (Hepatic metastasis):** This represents **Stage IV** disease. Any distant metastasis (liver, lung, peritoneum) automatically classifies the cancer as Stage IV, regardless of T or N status. * **Option C (Extension up to the serosa):** If the tumor extends to the serosa (T3) but has **no** lymph node involvement (N0), it is classified as **Stage II**. * **Option D (Extension up to the mucosa):** This describes a very early lesion (Tis or T1). Without nodal involvement, this is **Stage 0 or Stage I**. **3. High-Yield Clinical Pearls for NEET-PG:** * **Stage III Hallmark:** The defining feature of Stage III is **positive regional lymph nodes**. * **Treatment Shift:** While Stage I and II are often managed by surgery alone, **Stage III always requires adjuvant chemotherapy** (e.g., FOLFOX or CAPOX) because the risk of recurrence is high. * **Nodal Harvest:** For accurate staging, a minimum of **12 lymph nodes** must be examined pathologically. * **Most Common Site of Metastasis:** The **liver** (via the portal venous system), followed by the lungs.

Question 38: What is the management for a 51-year-old female with ductal carcinoma in situ?

A. Quadrentectomy
B. Simple mastectomy (Correct Answer)
C. Radiotherapy
D. Chemotherapy

Explanation: **Explanation:** The management of **Ductal Carcinoma in Situ (DCIS)** aims to prevent progression to invasive carcinoma. DCIS is a pre-invasive lesion where malignant cells are confined within the basement membrane of the breast ducts. **Why Simple Mastectomy is the Correct Answer:** In the context of the options provided, **Simple Mastectomy** (Total Mastectomy) is a definitive surgical treatment for DCIS. It is specifically indicated when the disease is multicentric, involves a large area relative to breast size, or when the patient prefers it over breast-conserving surgery (BCS). Unlike invasive cancer, DCIS does not typically spread to lymph nodes; therefore, a simple mastectomy (removing breast tissue and fascia) is sufficient without the need for routine Axillary Lymph Node Dissection (ALND). **Analysis of Incorrect Options:** * **A. Quadrentectomy:** While BCS (like wide local excision) is an option for localized DCIS, it must always be followed by radiotherapy to reduce recurrence. In exam scenarios, if "Simple Mastectomy" is an option against a partial resection without mentioned RT, mastectomy is the more "complete" surgical answer. * **C. Radiotherapy:** This is an adjuvant treatment used *after* breast-conserving surgery to reduce the risk of local recurrence. It is not a standalone primary treatment for DCIS. * **D. Chemotherapy:** DCIS is a non-invasive (Stage 0) cancer. Chemotherapy is reserved for invasive systemic disease and has no role in the management of DCIS. **NEET-PG High-Yield Pearls:** * **Gold Standard:** Breast Conserving Surgery (BCS) + Radiotherapy is equivalent to Mastectomy in terms of overall survival for DCIS. * **Sentinel Lymph Node Biopsy (SLNB):** While not routine for DCIS, SLNB is performed if a mastectomy is planned, as an invasive component might be found on final pathology, making later SLNB impossible. * **Tamoxifen:** Consider for 5 years post-surgery if the DCIS is ER-positive to reduce the risk of ipsilateral and contralateral breast cancer. * **Comedo Necrosis:** This histological subtype of DCIS has a higher risk of recurrence and progression to invasive cancer.

Question 39: Which of the following is true about Marjolin's ulcer?

A. Occurs over a chronic scar or burn (Correct Answer)
B. Characterized by rapid growth
C. Resembles a rodent ulcer
D. Typically painful

Explanation: **Explanation:** **Marjolin’s ulcer** is a classic example of a malignancy arising in a site of chronic inflammation or trauma. 1. **Why Option A is correct:** The fundamental concept behind Marjolin's ulcer is the malignant transformation (most commonly **Squamous Cell Carcinoma**) of a **chronic, unstable scar**, long-standing burn wound, or chronic osteomyelitis sinus. The chronic irritation and repeated cycles of healing and breakdown lead to genetic mutations in the epithelium. 2. **Why other options are incorrect:** * **Option B:** Marjolin’s ulcers are characterized by an **extremely long latent period**, often taking 20–30 years to develop. While they can become aggressive once established, "rapid growth" is not their defining feature compared to the slow, chronic evolution. * **Option C:** A "rodent ulcer" refers to **Basal Cell Carcinoma (BCC)**, which typically occurs on sun-exposed areas and has rolled-out edges. Marjolin’s ulcer is typically SCC and presents with everted edges. * **Option D:** These ulcers are typically **painless** because the scar tissue in which they develop is devoid of sensory nerve fibers. Pain is usually a late sign indicating deep invasion. **High-Yield Clinical Pearls for NEET-PG:** * **Most common site:** Lower limbs (specifically around the knee and ankle). * **Most common pathology:** Squamous Cell Carcinoma (SCC). * **Lymphadenopathy:** Usually absent initially because the dense scar tissue acts as a barrier to lymphatic spread. However, if it does spread, it is highly aggressive. * **Treatment:** Wide local excision (with 2 cm margins) or amputation, depending on the depth and location.

Question 40: What region of the pancreas is associated with the best prognosis in carcinoma?

A. Head
B. Tail
C. Body
D. Periampullary (Correct Answer)

Explanation: **Explanation:** The prognosis of pancreatic and peripancreatic cancers is primarily determined by the **timing of presentation** and the **resectability** at the time of diagnosis. **Why Periampullary is Correct:** Periampullary carcinomas (arising within 2 cm of the Ampulla of Vater) have the **best prognosis** because they present **early with "painless progressive jaundice"** due to biliary obstruction. This early clinical sign leads to prompt investigation and a higher rate of surgical resectability (Whipple’s procedure) compared to tumors in other locations. The 5-year survival rate for periampullary tumors (especially ampullary) is significantly higher (30–50%) than ductal adenocarcinoma of the pancreas (<5–10%). **Why Other Options are Incorrect:** * **Head of Pancreas:** While these also present with jaundice, they are biologically more aggressive than true periampullary tumors. By the time they cause symptoms, they often involve the portal vein or superior mesenteric artery, limiting resectability. * **Body and Tail:** These regions are the **"silent areas"** of the pancreas. Tumors here do not cause early biliary obstruction. They typically present very late with non-specific symptoms like weight loss or back pain, by which time they have usually metastasized or involved major vessels, making them unresectable and carrying the **worst prognosis**. **High-Yield Clinical Pearls for NEET-PG:** * **Courvoisier’s Law:** In a patient with painless jaundice and a palpable gallbladder, the cause is unlikely to be gallstones (usually signifies periampullary malignancy). * **Most common periampullary tumor:** Carcinoma of the Head of the Pancreas (but Ampullary CA has the best prognosis). * **Tumor Marker:** CA 19-9 is used for monitoring response to treatment, not for screening. * **Investigation of Choice:** Triple-phase Contrast-Enhanced CT (CECT) is the gold standard for staging and assessing resectability.

Practice by Chapter

Cancer Biology Basics

Practice Questions

Principles of Cancer Therapy

Practice Questions

Screening and Early Detection

Practice Questions

Surgical Staging

Practice Questions

Surgical Resection Principles

Practice Questions

Lymphadenectomy

Practice Questions

Management of Metastatic Disease

Practice Questions

Combined Modality Therapy

Practice Questions

Targeted Therapy Concepts

Practice Questions

Cancer Survivorship

Practice Questions

Palliative Surgical Interventions

Practice Questions

Ethics in Cancer Care

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free